Emergent BioSolutions (EBS) Tops Q2 EPS by 26c
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $7.90 +0.64%
Revenue Growth %: +32.0%
Financial Fact:
Other income (expense), net: -234K
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +32.0%
Financial Fact:
Other income (expense), net: -234K
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Emergent BioSolutions (NYSE: EBS) reported Q2 EPS of $0.16, $0.26 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $140.9 million versus the consensus estimate of $174 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Cushman & Wakefield names two capital markets leaders in APAC
- Zeta Surgical begins TMS navigation treatments at Hope Therapeutics clinics
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
